podcasts Ratings /ratings/en/research-insights/podcasts/2020-09-21-the-sp-pharma-dose-episode-36-what-bausch-remainco-s-credit-quality-post-spinoff-could-look-like content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

In This List

The S&P Pharma Dose - Episode 36: What Bausch RemainCo’s Credit Quality Post-Spinoff Could Look Like

COMMENTS

U.S. Restaurants And Foodservice Distributors Face A Jagged Recovery While Food And Beverage Fare Better

RESUPD

Research Update: Santos Ltd. 'BBB-' Ratings Affirmed, Outlook Stable

RESUPD

Research Update: Woodside Petroleum Ltd. 'BBB+' Ratings Affirmed; Outlook Negative

COMMENTS

COVID-19 Impact: Key Takeaways From Our Articles

Listen: The S&P Pharma Dose - Episode 36: What Bausch RemainCo’s Credit Quality Post-Spinoff Could Look Like

In this episode, Ji Liu, primary analyst for Bausch Health, discusses a number of investor questions after Bausch announced its intention to spin off its eye health business unit, specifically regarding its capital structure, key business strengths, key business weaknesses, and other concerns.

Register with S&P Global Ratings

Register now to access exclusive content, events, tools, and more.

Go Back